BRIM Biotechnology, Inc. (TPE:6885)

Taiwan · Delayed Price · Currency is TWD

29.10

+0.55 (1.93%)

Nov 13, 2026, 1:30 PM CST

Market Cap	3.87B -1.0%
Revenue (ttm)	12.55M +295.6%
Net Income	-440.46M
EPS	-3.35
Shares Out	133.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	508,339
Open	29.05
Previous Close	28.55
Day's Range	28.85 - 29.80
52-Week Range	20.05 - 34.65
Beta	0.74
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 12, 2027

About BRIM Biotechnology

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company’s lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease. It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that ha... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2013

Country Taiwan

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6885

Full Company Profile

Financial Performance

In 2025, BRIM Biotechnology's revenue was 5.49 million, an increase of 1548.65% compared to the previous year's 333,000. Losses were -436.45 million, 38.3% more than in 2024.

Financial Statements